Cell Therapeutics: Enticing To All, Convincing To None
The Behavioral Economist • 30 Comments
The Behavioral Economist • 30 Comments
Mar. 9, 2015, 9:12 AM
Mar. 9, 2015, 8:34 AM
- Small cap CTI BioPharma (NASDAQ:CTIC) jumps 19% premarket on robust volume in response to its announcement of positive results in a Phase 3 clinical trial evaluating Fast Track-designated pacritinib in patients with primary or secondary myelofibrosis, a rare bone marrow cancer. The study met its primary endpoint, the proportion of patients achieving a 35% reduction in spleen volume from baseline at Week 24, in the intent-to-treat population with statistically significant activity in patients irrespective of their initial platelet count, including those with thrombocytopenia, a severe and life-threatening condition.
- Pacritinib is an oral tyrosine kinase inhibitor (TKI) with activity against two key activating mutations: Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). The JAK family of enzymes plays an essential role in normal blood cell growth and the development of inflammatory and immune responses. Activated JAK2 mutations are implicated in certain blood cancers, including leukemia.
- Consultant Hematologist Claire Harrison, M.D., says, "Despite the introduction of JAK2 inhibitors as effective therapies for patients with myelofibrosis, there remains a treatment gap for patients with disease-related or treatment-emergent thrombocytopenia. Results from [this study] demonstrate that pacritinib could address this unmet medical need."
- Pacritinib is currently being evaluated in two Phase 3 studies that will support a New Drug Application (NDA) filing. It is being co-developed with Baxter International (NYSE:BAX). CTIC retains exclusive commercialization rights in the U.S. while Baxter has exclusive rights ex-U.S.
Jan. 13, 2015, 9:24 AM
Jan. 13, 2015, 8:04 AM
Dec. 4, 2014, 7:46 AM
- CTI BioPharma (NASDAQ:CTIC) receives a $15M milestone payment from Teva Pharmaceutical Industries (NYSE:TEVA) related to sales of the leukemia drug Trisenox (arsenic trioxide). CTI is eligible to receive up to an additional $80M in sales- and development-related milestones.
- Teva obtained the rights to the drug via its acquisition of Cephalon which acquired Trisenox from CTI.
Nov. 7, 2014, 9:14 AM
- Gainers: MITK +29%. RMTI +27%. RPRX +24%. SHLD +22%. CNET +15%. NETE +11%. PGNX +10%. ZNGA +9%. APT +9%. KING +9%. KING +9%. KGC +8%. TKMR +7%. AGIO +7%. BEBE +5%.
- Losers: SLXP -35%. MDRX -20%. CTIC -19%. ICPT -19%. UBNT -17%. ANF -13%. ANET -11%. ORBC -10%. AVNR -7%. FSLR -7%. PLNR -6%. NDLS -6%. RIG -5%. DVA -5%. NADL -5%.
Oct. 29, 2014, 7:00 PM
- CTI BioPharma Corp (CTIC -5.1%) Q3 results: Revenues: $39.5M (+9775.0%); Operating Expenses: $31.8M (+101.3%); Operating Income: $7.5M (+148.4%); Net Income: $4.6M (+129.9%); EPS: $0.03 (+115.0%); Quick Assets: $29.9M (-58.2%).
- 2014 Guidance: Non-GAAP Operating Loss: $66M - 71M from $45M - 50M.
Oct. 29, 2014, 4:09 PM
- CTI BioPharma (NASDAQ:CTIC): Q3 EPS of -$0.03 in-line.
- Revenue of $39.53M (+9782.5% Y/Y) beats by $15.23M.
Sep. 17, 2014, 9:15 AM
Sep. 17, 2014, 8:19 AM
- CTI BioPharma (NASDAQ:CTIC) and French drug firm Servier enter into an exclusive license and collaboration agreement to develop and commercialize Pixuvri (pixantrone). The drug is conditionally approved in the EU as a treatment for patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed two or three lines of therapy. It is the only monotherapy treatment option for this group of patients and is available in 11 countries.
- Under the terms of the agreement, CTI will receive an upfront payment of €14M (~$18.1M) and is eligible to receive additional sales, clinical and regulatory milestone payments and royalties on sales. The total value of the deal to CTI could reach €103M (~$133.5M).
- CTI retains full commercial rights to Pixuvri in Austria, Denmark, Finland, Germany, Israel, Norway, Sweden, Turkey, U.S. and the UK. Servier has exclusive rights for all other countries.
- CTIC is up 10% premarket on robust volume.
Sep. 9, 2014, 9:24 AM
Sep. 9, 2014, 8:00 AM
- Shares of micro cap CTI BioPharma (NASDAQ:CTIC) are up 9% premarket on average volume. Yesterday, Piper Jaffray initiated coverage with an "overweight" rating and a $6 PT. The average rating of all analysts covering the stock is "Buy" with an average PT of $5.13. Shares closed yesterday at $2.48.
- About a month ago, the FDA designated the company's late stage myelofibrosis product candidate, pacritinib, Fast Track.
Aug. 7, 2014, 1:45 PM
Aug. 7, 2014, 9:21 AM
Aug. 5, 2014, 9:17 AM
Aug. 4, 2014, 4:37 PM
- CTI BioPharma Corp. (CTIC +2.9%) Q2 results: Total Revenues: $1.3M (+338.9%); Operating Costs: $28.0M (+53.8%); Operating Loss: ($26.7M) (-49.2%); Net Loss: ($27.4M) (-52.2%); Loss Per Share: ($0.19) (-11.8%); Quick Assets: $33.2M (-53.6%).
- No guidance given.
CTI BioPharma Corp. operates as a biopharmaceutical company, which is focused on the acquisition, development, and commercialization of less toxic and more effective ways to treat cancer. Its products include Pixuvri, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco,... More
Country: United States
Other News & PR